GlassScriptPhysician profile
Dante Gamboa
NPI 1245346469
$2,706.25
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,259 · 2020: $423 · 2021: $24.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $766.02 | 2019-2020 | |
| Alkermes, INC. | $723.95 | 2019-2020 | |
| Allergan, INC. | $383.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $377.95 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $203.65 | 2019-2020 | |
| Lundbeck LLC | $199.42 | 2019-2021 | |
| Indivior INC. | $34.19 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dante Gamboa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.